Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05017935 · ClinicalTrials.gov registry record · NA

RADIANCE Continued Access Protocol

A NA study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.

Active
Registry status
NA
Development phase
300
Enrollment target
20
Study locations

NCT05017935 is a NA study of Hypertension and Cardiovascular Diseases that is active but no longer recruiting, run by ReCor Medical. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05017935, a NA study of Hypertension and Cardiovascular Diseases, is active but no longer recruiting, sponsored by ReCor Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications.

Conditions Studied

Hypertension Cardiovascular Diseases Vascular Diseases Hypertension, Resistant to Conventional Therapy

Interventions

  • DEVICE Renal Denervation

Study Locations (20)

California

  • Cardiovascular Institute of San Diego - Chula Vista
  • Cedars-Sinai Medical Center - Los Angeles
  • Sutter Health - Sacramento
  • Pacific Heart Institute - Santa Monica

Florida

  • The Cardiac and Vascular Institute - Gainesville
  • Baptist Hospital of Miami - Miami
  • Orlando Health - Orlando

Illinois

  • Northwestern University - Chicago
  • Prairie Education and Research Cooperative - Springfield
  • SIU Medicine - Springfield

Massachusetts

  • Boston Medical Center - Boston
  • The Brigham and Women's Hospital - Boston
  • UMASS Memorial Medical Center - Worcester

Maryland

  • Lifebridge Health - Baltimore
  • Tidal Health - Salisbury

Connecticut

  • Bridgeport Hospital - Bridgeport

Georgia

  • Emory - Atlanta

Indiana

  • Parkview Research Center - Fort Wayne

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-05-04
Est. Completion 2028-12-31
Phase NA

Sponsor

ReCor Medical

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05017935

The ClinicalTrials.gov registry entry for NCT05017935 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is ReCor Medical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Renal Denervation is the first listed.

NCT05017935 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05017935 about?

NCT05017935 is a clinical study titled "RADIANCE Continued Access Protocol". RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihyperten...

What is the current status of trial NCT05017935?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-05-04. Estimated completion is 2028-12-31.

What conditions does trial NCT05017935 study?

This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases, Hypertension, Resistant to Conventional Therapy.

What interventions are being tested in trial NCT05017935?

The interventions under investigation include: Renal Denervation (DEVICE).

Who is sponsoring clinical trial NCT05017935?

This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05017935 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Cardiovascular Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.